Pediatric phase I trial and pharmacokinetic study of dasatinib: A report from the children's oncology group phase I consortium

Journal of Clinical Oncology

Volumn 29, Issue 7, 2011, Pages 839-844

  Aplenc, Richard ^a   Blaney, Susan M ^a   Strauss, Lewis C ^a   Balis, Frank M ^a   Shusterman, Suzanne ^a   Ingle, Ashish Mark ^a   Agrawal, Shruti ^a   Sun, Junfeng ^a   Wright, John J ^a   Adamson, Peter C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DASATINIB; HYDROXYUREA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOID CYSTIC CARCINOMA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOGENETICS; DIARRHEA; DRUG DISPOSITION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEMANGIOMATOSIS; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; LEIOMYOSARCOMA; LEUKEMIA; MACULOPAPULAR RASH; MALE; PEDIATRICS; PHASE 3 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; SCHOOL CHILD; SIDE EFFECT; SOLID TUMOR; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HOSPITALS, PEDIATRIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; PATIENT SELECTION; PEDIATRICS; PHILADELPHIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RISK ASSESSMENT; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952319155     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.7231     Document Type: Article

References (12)

1. Shah NP, Tran C, Lee FY, et al: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401, 2004 (Pubitemid 38938156)
2. Kantarjian H, O'Brien S, Cortes J, et al: Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113:1933-1952, 2008
3. Kolb EA, Gorlick R, Houghton PJ, et al: Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 50:1198-1206, 2008 (Pubitemid 351555544)
4. Cortes J, Rousselot P, Kim DW, et al: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207-3213, 2007 (Pubitemid 46572505)
5. Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med 354:2531-2541, 2006
6. Hochhaus A, Kantarjian HM, Baccarani M, et al: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309, 2007 (Pubitemid 46425867)
7. Ottmann O, Dombret H, Martinelli G, et al: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood 110:2309-2315, 2007 (Pubitemid 47523149)
8. Demetri GD, Lo Russo P, MacPherson IR, et al: Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15:6232-6240, 2009
9. Jaffe CC: Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:3245-3251, 2006
10. Kantarjian H, O'Brien S, Shan J, et al: Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: Need for new response definitions? Cancer 112:837-845, 2008
11. Shah NP, Kantarjian HM, Kim DW, et al: Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronicphase chronic myeloid leukemia. J Clin Oncol 26: 3204-3212, 2008
12. Christopher LJ, Cui D, Wu C, et al: Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36:1357-1364, 2008 (Pubitemid 351929320)